locally advanced or metastatic urothelial carcinoma

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:disease
gptkbp:affectsOrgan	gptkb:ureter urethra bladder renal pelvis
gptkbp:alternativeName	advanced urothelial carcinoma metastatic bladder cancer
gptkbp:hasCommonDrug	gptkb:atezolizumab gptkb:carboplatin gptkb:erdafitinib gptkb:enfortumab_vedotin gptkb:cisplatin gptkb:pembrolizumab
gptkbp:hasDiagnosticMethod	imaging biopsy urine cytology
gptkbp:hasLocation	urinary tract
gptkbp:hasMedianSurvival	12-15 months
gptkbp:hasMetastasisSite	gptkb:cancer gptkb:bone liver lymph nodes
gptkbp:hasPrimaryTreatment	chemotherapy immunotherapy targeted therapy
https://www.w3.org/2000/01/rdf-schema#label	locally advanced or metastatic urothelial carcinoma
gptkbp:ICD-10_code	gptkb:C67
gptkbp:prognosis	poor
gptkbp:riskFactor	smoking chronic bladder inflammation exposure to chemicals
gptkbp:stageName	locally advanced metastatic
gptkbp:subclassOf	gptkb:urothelial_carcinoma
gptkbp:symptom	weight loss hematuria pelvic pain dysuria
gptkbp:bfsParent	gptkb:Durvalumab
gptkbp:bfsLayer	6